Caren van Roekel

155 Mode of progression after radioembolization in colorectal cancer patients Proper selection and individualized dosimetry-based treatment planning should ultimately lead to improved treatment accuracy in mCRC patients. CONCLUSIONS In conclusion, response at three-month follow-up and survival were heavily influenced by new intra- and extrahepatic metastases. Patients with extrahepatic disease at baseline had a worse outcome compared to patients without extrahepatic disease at baseline. Based on the results of this observational, retrospective study, extrahepatic disease may be considered a contraindication for treatment with radioembolization. LIST OF ABBREVIATIONS 90 Y yttrium-90 166 Ho holmium-166 BSA body surface area CR complete response CRC colorectal cancer mCRC colorectal cancer metastases MIRD medical internal adiation dose OS overall survival HCC hepatocellular carcinoma HEPAR-2 HolmiumEmbolization Particles for Arterial Radiotherapy II HR hazard ratio PD progressive disease PFS progression-free survival PR partial response RADAR RADioembolization: Angiogenic factors and Response RECIST response evaluation criteria in solid tumors SD stable disease 5